Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of canagliflozin in diabetic kidney disease
ChiCTR2000032137Phase 4Recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of canagliflozin in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoints: Serum creatinine and Glycosylated hemoglobin. Started May 2020; status: recruiting.
02
Drugs
canagliflozin
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000032137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032137.